Abstract
The notion of oligometastatic disease applies to a subpopulation of patients with a low tumour burden characterized clinically by a limited number of metastases. These oligometastatic stages may benefit from enhanced therapeutic approaches combining systemic treatment with local ablative treatments of the metastases and the primary tumour, using surgery, conventional or stereotactic radiotherapy and interventional radiology. Immunotherapy combined with radiotherapy is also being evaluated in this particular clinical situation. However, identifying patients who are candidates for such therapeutic strategies remains difficult, due to the heterogeneity of the situations and the still limited level of evidence, based on small prospective trials, with the need to avoid adding significant toxicities.1877-1203/© 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
